Top

Published in:

01-06-2010 | Case Report

Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma

Authors: Hiroyuki Takamatsu, Takeshi Yamashita, Takeharu Kotani, Aiko Sawazaki, Hirokazu Okumura, Shinji Nakao

Published in: International Journal of Hematology | Issue 5/2010

Abstract

A 79-year-old female patient with multiple myeloma who had no prior cardiac disease history developed an acute myocardial infarction on day 5 after receiving bortezomib and dexamethasone (BD). After treatment of coronary stenoses by stents, she received another course of BD therapy and developed angina pectoris on day 5 after the therapy. Bortezomib’s antitumor effect is due to the inhibition of proteasome activity. This inhibition may increase endothelial progenitor cell apoptosis and decrease endothelial nitric oxide synthase/nitric oxide (eNOS/NO), thus leading to coronary spasm. It is, therefore, important to carefully monitor patients being treated with bortezomib for the potential occurrence of ischemic heart disease.

Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–60.CrossRefPubMed

Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev. 2003;29(Suppl 1):33–9.CrossRefPubMed

Suvannasankha A, Smith GG, Juliar BE, Abonour R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma. 2006;7:131–4.CrossRefPubMed

Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006;6:129.CrossRefPubMed

Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol. 2008;88:219–22.CrossRefPubMed

Orciuolo E, Buda G, Cecconi N, Galimberti S, Versari D, Cervetti G, Salvetti A, Petrini M. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol. 2007;138:396–7.CrossRef

Foley PW, Hamilton MS, Leyva F. Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown). 2010;11:386–8.

Wada M, Mizoguchi H, Kuriya SI, Taguchi H, Kawamura T, Maekawa I, Shimazaki C, Sato Y, Niho Y, Miyazaki T, Shibata A, Kitani T, Hamajima N, Ohno R. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan. Br J Haematol. 2000;109:805–14.CrossRefPubMed

Martino M, Console G, Callea V, Stelitano C, Massara E, Irrera G, Messina G, Morabito F, Iacopino P. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. Eur J Haematol. 2007;78:35–40.CrossRefPubMed

10.

Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.CrossRefPubMed

11.

Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P, Blann AD. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thromb Haemost. 2005;94:797–801.PubMed

12.

Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox C, Brinker J, Lima JA. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med. 2008;359:2324–36.CrossRefPubMed

13.

Miller JM, Dewey M, Vavere AL, Rochitte CE, Niinuma H, Arbab-Zadeh A, Paul N, Hoe J, de Roos A, Yoshioka K, Lemos PA, Bush DE, Lardo AC, Texter J, Brinker J, Cox C, Clouse ME, Lima JA. Coronary CT angiography using 64 detector rows: methods and design of the multi-centre trial CORE-64. Eur Radiol. 2009;19:816–28.CrossRefPubMed

14.

Nagao M, Matsuoka H, Kawakami H, Higashino H, Mochizuki T, Ohshita A, Kohno T, Shigemi S. Detection of myocardial ischemia using 64-slice MDCT. Circ J. 2009;73:905–11.CrossRefPubMed

15.

Hu XS, Du CQ, Yang L, Yao XY, Hu SJ. Proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells: involvement of nitric oxide synthase inhibition. Int J Mol Med. 2010;25:385–92.CrossRefPubMed

16.

Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K. T-786– > C mutation in the 5’-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999;99:2864–70.PubMed

17.

Govers R, de Bree P, Rabelink TJ. Involvement of the proteasome in activation of endothelial nitric oxide synthase. Life Sci. 2003;73:2225–36.CrossRefPubMed

18.

Belloni D, Veschini L, Foglieni C, Dell’Antonio G, Caligaris-Cappio F, Ferrarini M, Ferrero E. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res. 2010;316:1010–8.CrossRefPubMed

19.

Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM, Stangl K. Ubiquitin–proteasome pathway as a new target for the prevention of restenosis. Circulation. 2002;105:483–9.CrossRefPubMed

20.

Martinet W, Kockx MM. Apoptosis in atherosclerosis: implications for plaque destabilization. Verh K Acad Geneeskd Belg. 2004;66:61–79.PubMed

21.

Kavurma MM, Bhindi R, Lowe HC, Chesterman C, Khachigian LM. Vessel wall apoptosis and atherosclerotic plaque instability. J Thromb Haemost. 2005;3:465–72.CrossRefPubMed

22.

Versari D, Herrmann J, Gossl M, Mannheim D, Sattler K, Meyer FB, Lerman LO, Lerman A. Dysregulation of the ubiquitin–proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2132–9.CrossRefPubMed

Title: Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma
Authors: Hiroyuki Takamatsu
Takeshi Yamashita
Takeharu Kotani
Aiko Sawazaki
Hirokazu Okumura
Shinji Nakao
Publication date: 01-06-2010
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0586-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group

Late effects in survivors of childhood acute lymphoblastic leukemia: a study from Thai Pediatric Oncology Group

Prevention of venous thromboembolism according to the guidelines of a domestic manual

Late effects and quality of life of childhood cancer survivors: Part 1. Impact of stem cell transplantation

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

Extramedullary plasmacytoma of the dura mimicking meningioma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer